Health records shall contain the date the lot was established (if using the unique lot method), the first date the animal(s) may be shipped for slaughter considering the requirement for at least a 180 day recorded history prior to slaughter, the unique identifier, as well as record entries that indicate the date the illness was noticed, the details of the illness, the number of animals affected and date the illness was resolved. Each record event entry shall be accompanied by the initials of the person making the entry and date/time of the entry.
Androgenic side effects, although much lesser than Testosterone, are still a possibility with Equipoise. Although Equipoise interacts with the 5AR (5-alpha reductase) enzyme, which is the enzyme responsible for the conversion of Testosterone into the stronger androgen DHT (Dihydrotestosterone), it does not convert into DHT but instead converts into Dihydroboldenone (DHB). Although it converts into DHB, studies have found Equipoise to undergo this conversion at a much lower rate than the conversion of Testosterone into DHT. Androgenic side effects can include: increased oily skin (sebum secretion), increased acne formation (linked to sebum secretion), bodily and facial hair growth, and the increased risk of experiencing male pattern baldness (MPB) if the individual possesses the genetic predisposition for it.